Affiliation: McGill University
- Evaluation of the efficacy and safety of etoricoxib in the treatment of hemophilic arthropathyChristos Tsoukas
McGill University Health Centre, Montreal General Hospital, 1650 Cedar Ave, Rm A5 140, Montreal, QC H3G 1A4, Canada
Blood 107:1785-90. 2006..6%) and during part 2 between etoricoxib (77.0%) and rofecoxib (78.9%). We conclude that etoricoxib provided superior efficacy versus placebo for the treatment of hemophilic arthropathy and was generally safe and well tolerated...
- Regional differences in rates of HIV-1 viral load monitoring in Canada: Insights and implications for antiretroviral care in high income countriesJanet M Raboud
Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
BMC Infect Dis 10:40. 2010....
- T cell Activation does not drive CD4 decline in longitudinally followed HIV-infected Elite ControllersPhilomena Kamya
Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
AIDS Res Ther 8:20. 2011..abstract:..
- Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infectionSabine Kinloch-de Loes
Department of Medicine, Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, London, United Kingdom
J Infect Dis 192:607-17. 2005..Our trial design appears to be feasible and safe for testing future immune-boosting strategies...
- Maraviroc for previously treated patients with R5 HIV-1 infectionRoy M Gulick
Weill Cornell Medical College, New York, NY 10065, USA
N Engl J Med 359:1429-41. 2008..CC chemokine receptor 5 antagonists are a new class of antiretroviral agents...
- Subgroup analyses of maraviroc in previously treated R5 HIV-1 infectionGerd Fatkenheuer
Universitätsklinik Köln, Cologne, Germany
N Engl J Med 359:1442-55. 2008....